Table 3.
EGFR status subgroup analysis of the ALTER0303 trial
EGFR status | Median OS (months) | HR (95% CI) | P value | |
---|---|---|---|---|
Placebo arm | Anlotinib arm | |||
Wild-type | 6.47 | 8.87 | 0.73 (0.55–0.97) | 0.022 |
Sensitive mutationsa | 6.27 | 10.70 | 0.59 (0.38–0.94) | 0.023 |
EGFR, epidermal growth factor receptor; OS, overall survival; HR, hazard ratio
aSensitive mutations include exon 19 deletion and exon 21 Leu858Arg